

Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease

Submission date 28/02/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 01/05/2007	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 05/09/2007	Condition category Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Klaus Leenders

Contact details
University Medical Center Groningen (UMCG)
Hanzeplein 1
Groningen
Netherlands
9700 RB

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
16901

Study information

Scientific Title

Acronym

COXPKPD (COX-2 inhibition monitored by PK11195 in Parkinson's Disease)

Study objectives

Celecoxib inhibits cerebral activated microglia in Parkinson's disease

Ethics approval required

Old ethics approval format

Ethics approval(s)

Medical Ethics Review Committee of the University Medical Center Groningen. Approval pending as of 28 February 2007.

Study design

Open, non-randomised, non-placebo controlled, pilot phase trial.

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet**Health condition(s) or problem(s) studied**

Parkinson's disease

Interventions

Interventions amended as of 05/09/2007:

All participants will receive celecoxib oral medication of 100 mg daily for 1 month.

Interventions provided at time of registration:

Celecoxib oral medication of 100 mg daily for 1 month.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Celecoxib

Primary outcome measure

One baseline and one follow-up Positron Emission Tomography (PET) scan (PK11195) and one Magnetic Resonance Imaging (MRI) scan will be performed to assess the reduction of specific cerebral radiotracer uptake (volume of distribution according to Logan graphical method) after celecoxib.

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/04/2007

Completion date

31/12/2007

Eligibility

Key inclusion criteria

1. Early Parkinson's disease patients
2. Hoehn and Yahr Parkinson's Disease Rating Scale (HY) 1 - 2

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

20

Key exclusion criteria

Gastrointestinal diseases

Date of first enrolment

01/04/2007

Date of final enrolment

31/12/2007

Locations

Countries of recruitment

Netherlands

Study participating centre

University Medical Center Groningen (UMCG)
Groningen
Netherlands
9700 RB

Sponsor information

Organisation

University Medical Center Groningen (UMCG) (The Netherlands)

Sponsor details

Hanzeplein 1
Groningen
Netherlands
9700 RB
k.l.leenders@neuro.umcg.nl

Sponsor type

University/education

ROR

<https://ror.org/03cv38k47>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

University Medical Center Groningen (UMCG) Neurology department departmental funding (The Netherlands)

Funder Name

Stichting International Parkinson Fonds (The Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration